Contents

Monobactam

Monocyclic β-lactam antibiotics

Aztreonam
Drug class
Aztreonam. (The four-membered ring at the bottom is the β-lactam. There is a second thiazole ring, but it is not fused to the β-lactam ring.)
Class identifiers
Use	Bacterial infection
ATC code	J01DF
External links
MeSH	D008997
Legal status
In Wikidata

Monobactams are bacterially-produced monocyclic β-lactam antibiotics. The β-lactam ring is not fused to another ring, in contrast to most other β-lactams.^[1]

Monobactams are narrow-spectrum antibiotics^[2] effective only against (strictly or facultatively^[3]) aerobic Gram-negative bacilli,^[4][5][3] exhibiting a high level of resistance to beta-lactamases of these organisms.^[3] Due to their narrow spectrum, monobactams can be used to treat infections by susceptible bacteria without disrupting the patient's microbiota.^[2] Monobactams are nevertheless seldom used.^[2]

Aztreonam is the principal^[4] and sole commercially available member of monobactams.^[6] Other monobactams include tigemonam,^[7] nocardicin A, and tabtoxin.^{[citation needed]}

Monobactams exert their antibacterial effects by binding to penicillin-binding proteins (PBPs), thereby inhibiting bacterial wall synthesis.^[5] Monobactams exhibit poor affinity for PBPs of Gram-positive bacteria as well as of strictly anaerobic bacteria, resulting in a lack of significant antimicrobial activity against these kinds of organisms.^[3] Monobactams are synergetic with aminoglycosides, and piperacillin.^[5]

Bacterial resistance to monobactams have been observed, and is mediated by bacterial beta-lactamases.^[5]

Adverse effects to monobactams can include skin rash and occasional abnormal liver functions.^{[citation needed]}

Monobactam antibiotics exhibit no IgE cross-reactivity reactions with penicillin but have shown some cross reactivity with cephalosporins, most notably ceftazidime, which contains an identical side chain as aztreonam.^[8] Monobactams can trigger seizures in patients with history of seizures, although the risk is lower than with penicillins.^{[citation needed]}

Siderophore-conjugated monobactams show promise for the treatment of multi drug-resistant pathogens.^[9]

• Monobactams at the U.S. National Library of Medicine Medical Subject Headings (MeSH)